With the competition watchdog's final remedies order now published, CVS Group is leaning on buybacks, Australian expansion and a return to like-for-like growth to rebuild its investment story.
For much of the past two years, the shadow of the Competition and Markets Authority's investigation into the UK veterinary market has hung over CVS Group (LSE:CVSG). That chapter has now formally closed. The CMA published its final remedies order on 22 September, and when the group reported full-year results two days later it said the outcome was in line with its expectations. The focus has since shifted to execution, capital returns and the search for a new chief executive.
Results show steady progress
In the year to 30 June 2026, revenue increased 5.9% to £712.8m, with like-for-like sales growth improving to 2.1% from just 0.2% the previous year. Adjusted EBITDA rose 5.1% to £141.5m, keeping the margin broadly stable at 19.9%, and adjusted earnings per share climbed 6.9% to 85.6p. Statutory profit before tax edged down 1.8% to £32.0m, held back by £10.6m of one-off items connected to the group's move from AIM to the Main Market and the costs of the CMA process. The company also flagged £5.1m of costs associated with implementing the remedies.
The board proposed a final dividend of 9.0p, up from 8.5p, which will go ex-dividend on 7 November and be paid on 4 December following the annual meeting on 25 November.
Capital returns and acquisitions
Shareholder returns have become a prominent feature of the story. CVS completed a £20m buyback in January and launched a further £50m programme on 26 May, which it expects to finish around November; regular transaction-in-own-shares notices, the latest on 12 October, show the purchases continuing. Combined, the two schemes will return around £70m in roughly a year. Non-executive director Laura Hagan added to her holding on 24 September, buying 4,128 shares at around 1,218p each.
The buybacks and acquisitions have pushed borrowing higher. Net bank debt rose to £199.6m from £131.4m, taking leverage to 1.63 times EBITDA, still comfortably inside the board's self-imposed ceiling of 2.0 times. The group has also refinanced its £350m facilities, extending them to May 2030 with an option for a further year.
Australia remains the main avenue for growth by acquisition. Revenue there increased to £79.1m from £52.1m, and the business now spans 57 sites across 35 practices, representing roughly 11% of group sales. CVS bought six Australian practices for £43.3m during the year and has acquired or agreed further deals since the year end. In the UK it has agreed to buy a two-site practice for an initial £15.0m.
Outlook and leadership transition
The company said the new financial year had started solidly with positive like-for-like growth, and it expects to perform in line with market expectations for the year to June 2027. The average of eleven analyst forecasts cited by the group points to adjusted EBITDA of around £150.4m and adjusted earnings per share of about 94.9p. Management continues to target medium-term like-for-like growth of between 4% and 8%, a range the latest year fell short of.
Chief executive Richard Fairman, who has said he intends to retire, argued that CVS (LSE:CVSG) is well placed to deliver long-term growth and that the end of the CMA investigation allows the business to concentrate fully on its operations. The search for his successor is ongoing, and the appointment, together with evidence on how the remedies affect pricing and client behaviour across UK practices, is likely to shape sentiment towards the shares in the months ahead.






Please wait processing your request...